Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases
By Kelly Cockerill, Vice President, Marsha Pelletier, Director, Philippe De Gaiffier, Consultant, and Carrie Jones, Partner
Rare Disease Day serves as a reminder of the ongoing collaborative effort in the healthcare industry to bring valuable new treatments for the over 300MM global rare disease patients.
Despite the rapidly advancing science and established unmet need for patients, rare disease drug manufacturers face several unique challenges when commercializing new products.
Health Advances, as a strategic healthcare and life sciences consulting firm, helps rare disease drug developers make smart decisions that will best position their products for broad patient access.
In our 30 years of work across the rare disease industry, we’ve identified several key success factors:
Interested in some of these examples? Please reach out to us or follow our blog so you don’t miss our future deep dives on these topics above and many more. https://healthadvancesblog.com
Contact
Carrie Jones [email protected], Partner leads Health Advances’ Rare and Orphan Disease Practice.
###
Related Insights
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Sep 22, 2026
Blog
Cell & Gene Unscripted: Real-world evidence
Sep 16, 2026
Blog
Cell & Gene Unscripted: Rare and genetic diseases
Sep 16, 2026
Blog
Cell & Gene Unscripted: Rethinking clinical research
Sep 16, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
Blog
Greater empathy, greater efficiency: How patient-first clinical development benefits all of us
Sep 10, 2026
Blog
The future of patient recruitment: Building a more connected ecosystem
Sep 9, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Related Insights
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Sep 22, 2026
Blog
Cell & Gene Unscripted: Real-world evidence
Sep 16, 2026
Blog
Cell & Gene Unscripted: Rare and genetic diseases
Sep 16, 2026
Blog
Cell & Gene Unscripted: Rethinking clinical research
Sep 16, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
Blog
Greater empathy, greater efficiency: How patient-first clinical development benefits all of us
Sep 10, 2026
Blog
The future of patient recruitment: Building a more connected ecosystem
Sep 9, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026